Company intelligence / Profile preview

Cleerly

Denver, Colorado, United Statescleerlyhealth.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cleerly’s FDA-cleared AI software analyzes non-invasive CCTA scans to detect and quantify atherosclerotic plaque and stenosis, enabling early identification of coronary artery disease and heart attack risk. The technology is validated by millions of images from multi-center trials and is now covered by Medicare with a CPT Category I code approved for advanced plaque analysis. Clinical studies such as CONFIRM2 are ongoing to further validate its impact on patient outcomes

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy (AI-driven diagnostic software)
Industry: Digital Health Medical Devices

Partnerships

Cardiac Care Alliance ("AI Meets Value-Based Care" partnership)

Beyond the preview

Go deeper on Cleerly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cleerly.

Explore the full profile